MasterClass Launches a Class on Dopamine to Help Members Balance Pleasure and Pain in an Overloaded World 
DLH to Announce Fiscal 2025 Third Quarter Financial Results
ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of...
New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox
Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovationGAITHERSBURG,...
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S....
Aclaris Therapeutics Announces Leadership Transition
- Roland Kolbeck, Ph.D. Appointed as Chief Scientific Officer - - Joe Monahan, Ph.D. will Continue to Support Aclaris as...
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy...
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued...
Fifty 1 Labs, Inc. to Host Virtual Shareholder Teleconference Featuring World-Class Leadership Team, including Dr. James Orbinski, who received the Nobel Peace Prize on Behalf of Médecins Sans Frontières
SEATTLE, July 28, 2025 (GLOBE NEWSWIRE) -- Fifty 1 Labs, Inc. (OTC: FITY), a leader in AI-powered health and wellness...
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"),...
NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025
Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to...
IMUNON Announces Stock Dividend Boosting Shareholder Value
Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July...
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025...
Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYPE Strategy
Increases total holdings to 1,535,772 HYPE Company to host investor webinar on Tuesday, July 29th at 2:00pm ET LAGUNA HILLS,...
NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01
TORONTO, July 28, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)...
Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results
SOMERSET, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell...
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025
NEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic...
UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology
PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and...
Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET
REDWOOD CITY, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel...
Chiesi Global Rare Diseases Spotlights the Profound Impact of Epidermolysis Bullosa in the Film “Living Between Pain and Hope” as part of “The Next Frontier,” a New Series Presented by the Biotechnology Innovation Organization
BOSTON, July 28, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases (Chiesi) proudly shares its contribution to the thought-provoking film...
Apyx Medical Corporation Announces Launch of Renuvion® in China
Strong clinical interest and early procedures completed Entered into distribution agreement with GlamMoon, a division of BeauCare Clinics Investment Co.,...
OncoC4 Announces New Preclinical Data Highlighting ONC-841, a Novel SIGLEC 10 Antibody, as a Potential New Class of Therapeutics for Alzheimer’s Disease
SIGLEC 10 identified as a genetic driver for amyloid plaque formation in mice ONC-841 blockade reduced amyloid plaques, normalized microglia...